![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | ( /ˌsaɪproʊˈhɛptədiːn/ [1] |
Trade names | Periactin, others |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a682541 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | First-generation antihistamine [2] [3] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 96 to 99% |
Metabolism | Liver [5] [6] Mostly CYP3A4 mediated. |
Elimination half-life | 8.6 hours [4] |
Excretion | Faecal (2-20%; 34% of this as unchanged drug) and renal (40%; none as unchanged drug) [5] [6] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H21N |
Molar mass | 287.406 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Cyproheptadine, sold under the brand name Periactin among others, is a first-generation antihistamine primarily used to treat allergies. [2] [3] This may include itchiness, hay fever, and hives. [3] It is taken by mouth. [2]
Common side effects include sleepiness, dizziness, agitation, and poor coordination. [2] Other side effects may include swelling, problems urinating, and increased weight. [3] There is no evidence of harm with use during pregnancy, however such use has not been well studied. [7] Care should be taken in those at risk of glaucoma. [3]
Cyproheptadine was patented in 1959 and came into medical use in 1961. [8] It is available as a generic medication. [9] In the United Kingdom 30 tablets of 4 mg costs the NHS about 6 pounds in 2020. [3] This amount in the United States costs about 10 USD. [9]